Literature DB >> 18800262

Infant acute lymphoblastic leukemia: a 20-year children's hospital experience.

Rebecca A F Murray1, Giddel Thom, Renee V Gardner, Randall D Craver.   

Abstract

We reviewed our 20-year experience with infant acute lymphoblastic leukemia (ALL). Nine infants (4.2% of all ALL) were identified; all were < 6 months of age. White blood cell counts ranged from 42,000-1.6 million/microL, 6 of 8 had hepatosplenomegaly, and 6 of 9 (66.6%) had central nervous system disease. Of 7 with cytogenetic information, 6 (85.7%) had diploidy; the remaining child was 47, XY,+8,del(21)(q22). Four had the MLL-11q23 abnormality. All received chemotherapy. Four underwent stem cell transplantation. Survival was 67%, (15 months-21 years). Deaths occurred at 9 months, 15 months (graft vs. host), and 7 years (complications of small bowel transplantation). Only 1 undergoing stem cell transplantation died. There were no late recurrences or second malignancies. Despite extensive disease and age < 6 months at diagnosis (a poor prognostic feature), for ALL patients our 67% survival is at least as good as reported, although it is less favorable than childhood ALL.

Entities:  

Mesh:

Year:  2008        PMID: 18800262     DOI: 10.1080/15513810802319392

Source DB:  PubMed          Journal:  Fetal Pediatr Pathol        ISSN: 1551-3815            Impact factor:   0.958


  2 in total

Review 1.  Does hematopoietic stem cell transplantation benefit infants with acute leukemia?

Authors:  Edward Allan R Sison; Patrick Brown
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

2.  Physiologically Based Pharmacokinetic Modeling of Fluorescently Labeled Block Copolymer Nanoparticles for Controlled Drug Delivery in Leukemia Therapy.

Authors:  M J Gilkey; V Krishnan; L Scheetz; X Jia; A K Rajasekaran; P S Dhurjati
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-03-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.